There are 2789 resources available
Invited Discussant LBA32 and 721O
Presenter: Rosalind Glasspool
Session: Proffered Paper session - Gynaecological cancers
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Rosalind Glasspool
Session: Proffered Paper session - Gynaecological cancers
Resources:
Slides
Webcast
Invited Discussant 722O and LBA33
Presenter: Clare Scott
Session: Proffered Paper session - Gynaecological cancers
Resources:
Slides
Webcast
Invited Discussant LBA38, 957O and 958O
Presenter: Sebastian Kobold
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Slides
Webcast
Invited Discussant 959O
Presenter: Alessandra Curioni
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Slides
Webcast
652O - Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
Presenter: Christian Pfister
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
1170O - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)
Presenter: Cécile Le Pechoux
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial
Presenter: Nicolas Girard
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA42 - COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC
Presenter: Alexandre Martinez-Marti
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA32 - Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Presenter: Susana Banerjee
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast